Peptides - Compound guides
BPC-157
BPC-157 is a synthetic peptide fragment studied almost entirely in animals and cell cultures, with essentially no published human clinical trial evidence.
BPC-157 stands for Body Protection Compound 157. It is a synthetic chain of fifteen amino acids whose sequence was derived from a protein found in human gastric juice. The parent protein is sometimes described in the literature as a gastric pentadecapeptide, and researchers working in Croatia in the 1990s isolated the fragment and began testing it in laboratory models. The compound does not exist in nature in the form that is sold today - it is a laboratory construct based on a naturally occurring sequence, and that distinction matters, because "derived from something found in the body" is not the same as "known to be safe or useful in the body".
Almost everything published about BPC-157 comes from a small number of research groups, and almost all of it was carried out in rats, mice and cell cultures. The compound has become extremely popular in online fitness and biohacking communities, where it is often discussed as though the science were settled. It is not. The gap between the confidence of the online conversation and the actual state of the published literature is one of the widest of any compound covered on this site, and understanding why is the most useful thing this lesson can give you.
How it is thought to work
The proposed mechanism most often described in the preclinical literature involves angiogenesis - the formation of new blood vessels. Researchers have reported that in animal tissue, BPC-157 appears to influence signalling around vascular endothelial growth factor, a molecule involved in building new capillaries. Because tissue repair depends heavily on blood supply, the hypothesis is that a compound which promotes vessel formation might influence how damaged tissue behaves. This is a plausible-sounding chain of reasoning, but it is a hypothesis built on animal data, not a demonstrated pathway in humans.
A second proposed mechanism concerns the nitric oxide system. Animal studies have reported effects on nitric oxide signalling, which is involved in blood flow regulation. A third strand of the literature has looked at interactions with growth factor receptors and with the gut-brain axis, since the parent protein came from the stomach lining. It is worth being clear about the epistemic status of all of this: these are proposed and partially characterised mechanisms observed in non-human systems. No mechanism for BPC-157 has been confirmed in living humans, because the studies that would confirm it have not been done.
What the research actually shows
On the evidence ladder - cells in a dish, then animals, then small human studies, then randomised controlled human trials - BPC-157 sits almost entirely on the bottom two rungs. There are a substantial number of rodent studies, published over roughly three decades, reporting effects in models of tendon injury, muscle damage, gut inflammation and wound healing. Those studies exist and are real. But they were largely produced by a small cluster of related research groups, which is a recognised limitation in evidence appraisal: independent replication by unrelated laboratories is what turns a promising finding into an established one, and that broad independent replication has not happened.
Human evidence is essentially absent. There is no body of published randomised controlled trials in humans establishing that BPC-157 does anything at all in people. A small number of early-stage human safety studies have been registered or referenced, but there is nothing resembling the trial programme that would be required to establish either efficacy or a safety profile. When you read a confident online claim that BPC-157 "heals tendons" or "repairs the gut", what is being described is a rodent finding presented as a human fact. That is a translation error, and the history of drug development is full of compounds that worked beautifully in rats and did nothing, or did harm, in humans.
Long-term safety data in humans does not exist. This is not a case of "the safety data is reassuring" - there is no meaningful human dataset to be reassured by. Concerns raised in theoretical discussion include the fact that a compound proposed to promote new blood vessel growth has an unclear relationship with tissue that you would not want to supply with new blood vessels, though it should be stressed this is a theoretical open question rather than a documented human finding.
Where the evidence stops
- No published randomised controlled trials in humans demonstrating any clinical effect.
- Animal findings have not been broadly replicated by independent, unrelated research groups.
- No established human pharmacokinetics - how the peptide is absorbed, distributed and cleared in people is not well characterised.
- No long-term human safety data of any kind, and no data in specific populations such as older adults or people with existing health conditions.
- The theoretical interaction between a pro-angiogenic compound and abnormal tissue growth remains an unresolved question rather than a settled one.
- Material sold as a research chemical is not subject to pharmaceutical quality control, so what is in a given vial is itself an unknown variable in any anecdotal report.
Legal and regulatory status
BPC-157 is not an approved medicine in the United Kingdom, and it is not approved as a medicine for general human use anywhere. It has no marketing authorisation from the MHRA and no equivalent approval from the European Medicines Agency or the US Food and Drug Administration. Where it is sold, it is typically labelled as a research chemical and marked as not for human consumption. That label is legally meaningful: products sold this way are not manufactured to pharmaceutical standards, are not tested for purity, sterility or correct identity, and carry no quality assurance that a licensed medicine would carry.
For anyone in competitive sport, BPC-157 was added to the World Anti-Doping Agency prohibited list in 2022, under the category covering growth factors and related compounds. It is prohibited at all times, in and out of competition. An athlete who tests positive faces the same consequences as for any other prohibited substance, and the "it was only a research chemical" framing carries no weight with anti-doping bodies.
This lesson is educational content only and is not medical advice. BPC-157 is not an approved medicine in the UK or elsewhere for any human use, and the human evidence base for it is essentially absent. Any decision relating to your health belongs with a qualified healthcare professional who knows your medical history.
Recovery and repair peptides
Start with the overview: Recovery and repair peptides, explained
Further reading
Sources for this classroom
Educational content only. Not medical advice, diagnosis or treatment. Always consult a qualified healthcare professional before changing your health regimen.
